Abingworth raises its biggest transatlantic biotech fund yet through $465m final close
Life science investor Abingworth has upped the ante yet again with its 13th fundraise by hitting a $465m final close for the fund.
Life science investor Abingworth has upped the ante yet again with its 13th fundraise by hitting a $465m final close for the fund.
European life sciences venture capital major Sofinnova Partners has brought on board experienced former Abingworth investor Joe Anderson as a partner.
